Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS G12C Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Testing effectiveness (Phase 2)WithdrawnNCT05815186
What this trial is testing

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Who this might be right for
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NYU Langone Health
Large-scale testing (Phase 3)Active Not RecruitingNCT04685135
What this trial is testing

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Who this might be right for
Metastatic Non Small Cell Lung CancerAdvanced Non Small Cell Lung Cancer
Mirati Therapeutics Inc. 453
Testing effectiveness (Phase 2)UnknownNCT05119933
What this trial is testing

A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

Who this might be right for
Advanced Solid Tumor
Shanghai YingLi Pharmaceutical Co. Ltd. 55
Early research (Phase 1)Looking for participantsNCT05815173
What this trial is testing

Ladarixin With Sotorasib in Advanced NSCLC

Who this might be right for
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NYU Langone Health 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06970132
What this trial is testing

Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation

Who this might be right for
Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD 102
Testing effectiveness (Phase 2)Study completedNCT05005234
What this trial is testing

GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

Who this might be right for
KRAS G12C
Innovent Biologics (Suzhou) Co. Ltd. 334
Not applicableStudy completedNCT05347745
What this trial is testing

Therascreen® KRAS RGQ PCR Kit

Who this might be right for
Colo-rectal Cancer
QIAGEN Gaithersburg, Inc 219
Testing effectiveness (Phase 2)Looking for participantsNCT07172919
What this trial is testing

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

Who this might be right for
Advanced Solid Tumors
Amgen 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT05853575
What this trial is testing

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplasm of Lung
Mirati Therapeutics Inc. 200
Early research (Phase 1)Active Not RecruitingNCT05485974
What this trial is testing

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Who this might be right for
Lung CancerNon Small Cell Lung CancerColorectal Cancer+4 more
HUYABIO International, LLC. 44
Early research (Phase 1)Looking for participantsNCT07094204
What this trial is testing

Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Who this might be right for
Solid TumorNon-Small-Cell Lung CancerPancreatic Ductal Adenocarcinoma+1 more
Astellas Pharma Inc 364
Testing effectiveness (Phase 2)Active Not RecruitingNCT05009329
What this trial is testing

JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Who this might be right for
NSCLCSolid Tumor
Allist Pharmaceuticals, Inc. 315
Testing effectiveness (Phase 2)Looking for participantsNCT07468071
What this trial is testing

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Who this might be right for
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung CancerAdvanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals 40
Early research (Phase 1)Study completedNCT04006301
What this trial is testing

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

Who this might be right for
NeoplasmsAdvanced Solid TumorsNon-small Cell Lung Cancer+1 more
Janssen Research & Development, LLC 10
Early research (Phase 1)UnknownNCT06006793
What this trial is testing

SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation

Who this might be right for
Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD 50
Testing effectiveness (Phase 2)Looking for participantsNCT05410145
What this trial is testing

D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Who this might be right for
KRAS P.G12C
D3 Bio (Wuxi) Co., Ltd 442
Large-scale testing (Phase 3)Looking for participantsNCT06300177
What this trial is testing

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Who this might be right for
Non Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 522
Large-scale testing (Phase 3)Looking for participantsNCT06252649
What this trial is testing

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Who this might be right for
Metastatic Colorectal Cancer
Amgen 450
Testing effectiveness (Phase 2)Study completedNCT03600883
What this trial is testing

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Who this might be right for
KRAS p.G12C Mutant Advanced Solid Tumors
Amgen 713
Next Page